Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Eletriptan hydrobromide
Drug ID BADD_D00756
Description Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.
Indications and Usage For the acute treatment of migraine with or without aura in adults.
Marketing Status approved; investigational
ATC Code N02CC06
DrugBank ID DB00216
KEGG ID D01973
MeSH ID C115647
PubChem ID 656631
TTD Drug ID D02DMQ
NDC Product Code 65015-719; 65162-042; 59651-104; 27241-040; 59651-105; 55700-756; 59762-2322; 10829-0558; 48087-0090; 0378-4288; 65162-043; 68382-922; 70771-1107; 48087-0102; 63126-904; 65977-0059; 68382-923; 71335-1830; 59762-2321; 0049-2330; 0378-4287; 70771-1108; 0093-8311; 63629-8320; 0049-2340; 10829-0557; 59651-101; 0093-8310; 27241-039
UNII M41W832TA3
Synonyms eletriptan | (R)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole | UK 166,044 | UK-166044 | UK 166044 | UK-166,044 | Relpax | UK-116044-04 | UK-116,044-04 | eletriptan hydrobromide | (R)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole monohydrobromide | 3-(1-methyl-2-pyrrolidinylmethyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole hydrobromide
Chemical Information
Molecular Formula C22H27BrN2O2S
CAS Registry Number 177834-92-3
SMILES CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4.Br
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder19.19.02.002; 22.12.03.027; 17.02.08.003--Not Available
Sputum increased22.02.03.007--Not Available
Stomatitis07.05.06.005--
Stupor19.02.05.004; 17.02.04.007--Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.007--Not Available
Tenosynovitis15.07.01.004--Not Available
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Throat tightness22.12.03.031; 19.01.02.005--Not Available
Thrombophlebitis24.01.02.001--Not Available
Thyroid adenoma05.02.05.003; 16.37.01.001--Not Available
Thyroiditis05.02.04.001--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue disorder07.14.01.002--Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.007--Not Available
Tooth disorder07.09.05.001--Not Available
Tremor17.01.06.002--
Urinary tract disorder20.08.01.001--Not Available
Urticaria10.01.06.001; 23.04.02.001--
Vaginal infection21.14.02.002; 11.01.10.002--
Vasospasm24.04.02.002--Not Available
Ventricular arrhythmia02.03.04.006--
Vertigo04.04.01.003; 17.02.12.002--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Yawning22.12.03.037--Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages